Alkem Laboratories Limited
NSE: ALKEM BSE: ALKEM
NSE
5,426.00
4.00 (0.07%)
Prev Close
5422
Open Price
5470
Volume
99,581
Today Low / High
5420 / 5479
52 WK Low / High
4491.65 / 6439.9
Range
5,155 - 5,697
BSE
5,425.80
3.15 (0.06%)
Prev Close
5422.65
Open Price
5451.05
Volume
3,272
Today Low / High
5419.9 / 5476.9
52 WK Low / High
4498.9 / 6440
Range
5,155 - 5,697
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 5426 (target range: 5,155 - 5,697), reflecting a change of 4 (0.07377352%). On the BSE, it is listed at 5425.8 (target range: 5,155 - 5,697), showing a change of 3.15 (0.05808968%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
22 Aug
5,470.00
-0.80%
21 Aug
5,393.00
0.54%
20 Aug
5,400.00
-0.13%
19 Aug
5,353.00
0.73%
18 Aug
5,347.50
-0.03%
14 Aug
5,355.00
-0.14%
13 Aug
5,240.00
2.83%
12 Aug
4,864.50
5.85%
11 Aug
4,769.50
1.57%
08 Aug
4,872.00
-2.22%
07 Aug
4,860.00
0.25%
06 Aug
4,929.00
-1.18%
05 Aug
4,892.00
0.59%
04 Aug
4,868.50
0.70%
01 Aug
5,032.00
-2.64%
31 Jul
5,098.00
-1.31%
30 Jul
5,071.00
0.56%
29 Jul
5,049.90
0.41%
28 Jul
4,994.90
1.05%
Alkem Laboratories Limited Graph
Alkem Laboratories Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Alkem Laboratories Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 5,426.00, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 5,425.80 | 5,480.06 | 4,932.05 - 6,028.06 |
| 5,534.32 | 4,427.45 - 6,641.18 | ||
| 5,588.57 | 3,912.00 - 7,265.15 | ||
| Bearish Scenario | 5,425.80 | 5,371.54 | 4,834.39 - 5,908.70 |
| 5,317.28 | 4,253.83 - 6,380.74 | ||
| 5,263.03 | 3,684.12 - 6,841.93 |
Overview of Alkem Laboratories Limited
ISIN
INE540L01014
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
193,143
Market Cap
648,759,690,000
Last Dividend
45
Official Website
IPO Date
2015-12-23
DCF Diff
-3,237.25
DCF
8,663
Financial Ratios Every Investor Needs
Stock Dividend of ALKEM
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-08-08 | August 08, 25 | 8 | 8 | 2025-08-08 | 2025-09-24 | |
| 2025-02-14 | February 14, 25 | 37 | 37 | 2025-02-14 | 2025-02-28 | |
| 2024-08-09 | August 09, 24 | 5 | 5 | 2024-08-10 | 2024-09-29 | |
| 2024-02-16 | February 16, 24 | 35 | 35 | 2024-02-17 | 2024-03-01 | |
| 2023-08-10 | August 10, 23 | 10 | 10 | 2023-08-10 | 2023-09-24 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 12,964.52 Cr | 4,764.26 Cr | 8,200.26 Cr | 0.6325 | 562.00 Cr | 316.98 Cr | 2,154.99 Cr | 2,165.48 Cr | 181.11 | 3,005.89 Cr | 0.1670 |
| 2024-03-31 | 12,567.30 Cr | 7,437.89 Cr | 5,129.41 Cr | 0.4082 | 0.00 Cr | 302.90 Cr | 1,984.86 Cr | 1,795.77 Cr | 150.19 | 2,419.51 Cr | 0.1429 |
| 2023-03-31 | 11,440.35 Cr | 5,020.73 Cr | 6,419.62 Cr | 0.5611 | 0.00 Cr | 299.14 Cr | 1,334.17 Cr | 984.17 Cr | 82.31 | 1,722.55 Cr | 0.0860 |
| 2022-03-31 | 10,512.03 Cr | 7,022.23 Cr | 3,489.80 Cr | 0.3320 | 0.00 Cr | 247.58 Cr | 1,769.17 Cr | 1,645.62 Cr | 137.63 | 2,190.66 Cr | 0.1565 |
| 2021-03-31 | 8,822.72 Cr | 5,849.58 Cr | 2,973.14 Cr | 0.3370 | 0.00 Cr | 222.68 Cr | 1,671.42 Cr | 1,585.02 Cr | 132.57 | 2,175.60 Cr | 0.1797 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 304.14 Cr | 17,691.10 Cr | 5,257.47 Cr | 11,984.8700 Cr | 1,380.90 Cr | 1,076.76 Cr | 2,922.41 Cr | 2,931.87 Cr | 0.00 Cr | 0.00 Cr | 1,328.69 Cr | 3,964.9800 Cr |
| 2024-03-31 | 455.07 Cr | 15,574.90 Cr | 4,860.50 Cr | 10,312.0600 Cr | 1,418.41 Cr | 963.34 Cr | 2,661.18 Cr | 2,557.03 Cr | 112.29 Cr | 0.00 Cr | 405.13 Cr | 3,994.5500 Cr |
| 2023-03-31 | 273.80 Cr | 13,756.65 Cr | 4,321.65 Cr | 9,045.2900 Cr | 1,396.68 Cr | 1,122.88 Cr | 2,607.53 Cr | 2,513.55 Cr | 73.97 Cr | 8.80 Cr | 524.87 Cr | 3,707.1500 Cr |
| 2022-03-31 | 232.18 Cr | 14,069.19 Cr | 5,221.86 Cr | 8,637.9000 Cr | 2,668.19 Cr | 2,436.01 Cr | 3,005.53 Cr | 2,659.10 Cr | 72.87 Cr | 7.92 Cr | 928.85 Cr | 4,805.3400 Cr |
| 2021-03-31 | 174.22 Cr | 11,519.26 Cr | 3,961.25 Cr | 7,376.7300 Cr | 1,791.98 Cr | 1,617.76 Cr | 2,312.44 Cr | 2,658.16 Cr | 0.00 Cr | 0.00 Cr | -1,420.90 Cr | 3,604.0500 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,912.8400 Cr | -1,298.7600 Cr | -810.9900 Cr | 1,237.2200 Cr | -186.4000 Cr | -120.0900 Cr | -675.6200 Cr | 2,527.0300 Cr | -194.1100 Cr | -504.6200 Cr | -261.2300 Cr |
| 2024-03-31 | 1,948.0700 Cr | -1,008.5000 Cr | -1,145.0100 Cr | 1,688.7800 Cr | -207.4900 Cr | 66.3100 Cr | -259.2900 Cr | 1,795.7700 Cr | -480.8900 Cr | -538.0400 Cr | -73.4000 Cr |
| 2023-03-31 | 1,682.5000 Cr | 112.8400 Cr | -1,760.8200 Cr | 1,449.5900 Cr | 41.6200 Cr | 273.8000 Cr | -232.9100 Cr | 1,304.7700 Cr | -1,278.4800 Cr | -529.5200 Cr | 473.4100 Cr |
| 2022-03-31 | 1,111.0200 Cr | -1,435.1300 Cr | 379.5700 Cr | 772.1400 Cr | 57.9600 Cr | 232.1800 Cr | -338.8800 Cr | 1,844.2800 Cr | 862.7800 Cr | -421.9100 Cr | -673.1400 Cr |
| 2021-03-31 | 1,264.9000 Cr | -998.5400 Cr | -271.7500 Cr | 1,069.9900 Cr | -1.7200 Cr | 174.2200 Cr | -194.9100 Cr | 1,842.1000 Cr | 139.6800 Cr | -334.7800 Cr | -497.7000 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 3,371.14 Cr | 1,171.16 Cr | 2,199.98 Cr | 0.6526 | 651.37 Cr | 664.26 Cr | 55.56 | 888.47 Cr | 0.1970 |
| 2025-03-31 | 3,143.75 Cr | 1,279.28 Cr | 1,864.47 Cr | 0.5931 | 278.80 Cr | 305.86 Cr | 25.58 | 537.25 Cr | 0.0973 |
| 2024-12-31 | 3,374.28 Cr | 1,204.33 Cr | 2,169.95 Cr | 0.6431 | 674.11 Cr | 625.82 Cr | 52.34 | 852.38 Cr | 0.1855 |
| 2024-09-30 | 3,414.67 Cr | 1,204.70 Cr | 2,209.97 Cr | 0.6472 | 673.92 Cr | 688.64 Cr | 57.60 | 887.31 Cr | 0.2017 |
| 2024-06-30 | 3,031.82 Cr | 1,758.70 Cr | 1,273.12 Cr | 0.4199 | 528.16 Cr | 545.16 Cr | 45.60 | 728.95 Cr | 0.1798 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 304.14 Cr | 4,195.63 Cr | 3,777.92 Cr | 2,475.29 Cr | 2,922.41 Cr | 10,945.82 Cr | 2,931.87 Cr | 17,691.10 Cr | 5,257.47 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 2,288.88 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -11,910.08 Cr |
| 2024-09-30 | 412.58 Cr | 336.63 Cr | 4,739.64 Cr | 2,512.80 Cr | 2,912.18 Cr | 11,109.28 Cr | 2,561.16 Cr | 17,117.03 Cr | 5,206.95 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 4,269.72 Cr | 0.00 Cr | 0.00 Cr | 4,269.72 Cr | 0.00 Cr | 0.00 Cr | -10,714.40 Cr |
| 2024-03-31 | 455.07 Cr | 3,814.65 Cr | 4,269.72 Cr | 2,285.46 Cr | 2,661.18 Cr | 10,411.58 Cr | 2,557.03 Cr | 15,574.90 Cr | 4,860.50 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 625.82 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 688.64 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 545.16 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 293.56 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 594.96 Cr | 139.12 Cr | 0.00 Cr | 0.00 Cr | 139.12 Cr | 3,439.80 Cr | 3,300.68 Cr | 0.00 Cr | 139.12 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,641.80 | ₹3,939,137,904,000.00 | ₹2,098,280.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,151.50 | ₹1,633,032,553,500.00 | ₹681,521.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,685.30 | ₹1,247,271,358,500.00 | ₹279,863.00 |
| Mankind Pharma Limited | MANKIND | ₹2,606.80 | ₹1,075,901,331,568.00 | ₹731,305.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,277.60 | ₹1,063,387,459,020.00 | ₹1,229,762.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹988.80 | ₹994,960,224,000.00 | ₹307,413.00 |
| Lupin Limited | LUPIN | ₹1,974.70 | ₹901,938,300,900.00 | ₹380,522.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,426.00 | ₹648,759,690,000.00 | ₹99,581.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,050.40 | ₹610,074,420,800.00 | ₹1,872,840.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,937.30 | ₹546,707,997,300.00 | ₹466,930.00 |
| Laurus Labs Limited | LAURUSLABS | ₹879.10 | ₹474,560,157,500.00 | ₹1,548,001.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,418.40 | ₹359,853,753,600.00 | ₹437,395.00 |
| Cohance Lifesciences Limited | COHANCE | ₹884.70 | ₹338,457,031,978.00 | ₹105,334.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,638.50 | ₹329,643,636,000.00 | ₹49,045.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,747.90 | ₹273,268,433,900.00 | ₹250,994.00 |
| Piramal Enterprises Limited | PEL | ₹1,167.70 | ₹264,691,900,600.00 | ₹183,898.00 |
| Eris Lifesciences Limited | ERIS | ₹1,768.70 | ₹240,909,320,900.00 | ₹37,828.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,479.40 | ₹240,371,432,600.00 | ₹246,819.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,433.00 | ₹210,825,000,000.00 | ₹11,150.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹974.60 | ₹191,570,299,800.00 | ₹29,498.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,888.00 | ₹178,181,651,200.00 | ₹28,474.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,083.00 | ₹172,501,323,000.00 | ₹140,398.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,168.10 | ₹164,800,966,770.00 | ₹172,510.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹882.45 | ₹158,055,619,500.00 | ₹259,072.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹458.50 | ₹111,252,274,000.00 | ₹945,550.00 |
| Procter & Gamble Health Limited | PGHL | ₹6,581.50 | ₹109,248,951,100.00 | ₹46,177.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹851.90 | ₹83,308,067,710.00 | ₹36,218.00 |
| Strides Pharma Science Limited | STAR | ₹865.50 | ₹79,775,471,850.00 | ₹92,326.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹863.25 | ₹78,240,335,715.00 | ₹294,141.00 |
| FDC Limited | FDC | ₹474.65 | ₹77,277,766,500.00 | ₹198,253.00 |
| Innova Captab Limited | INNOVACAP | ₹911.35 | ₹52,151,939,956.00 | ₹70,484.00 |
| Suven Life Sciences Limited | SUVEN | ₹230.75 | ₹50,320,575,500.00 | ₹56,095.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹146.08 | ₹47,406,173,760.00 | ₹195,028.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹483.05 | ₹44,087,973,500.00 | ₹160,106.00 |
| Sequent Scientific Limited | SEQUENT | ₹175.85 | ₹44,021,409,750.00 | ₹240,104.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹772.20 | ₹39,165,289,020.00 | ₹31,316.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,358.20 | ₹39,002,269,800.00 | ₹5,512.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹363.25 | ₹36,425,983,500.00 | ₹39,528.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹502.80 | ₹35,400,036,240.00 | ₹9,585.00 |
| Hikal Limited | HIKAL | ₹254.90 | ₹31,429,424,900.00 | ₹3,140,867.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹631.60 | ₹30,413,434,800.00 | ₹53,855.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹96.82 | ₹28,419,284,140.00 | ₹848,541.00 |
| Alembic Limited | ALEMBICLTD | ₹105.52 | ₹27,095,636,534.00 | ₹249,022.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹49.03 | ₹26,866,184,620.00 | ₹2,369,065.00 |
| Indoco Remedies Limited | INDOCO | ₹279.55 | ₹25,787,900,445.00 | ₹12,570.00 |
Key Executives
President & Head Medtech Business
Mr. Kaustav Banerjee
Gender: male
Year Born:
Executive Director
Mr. Srinivas Singh
Gender: male
Year Born: 1989
Vice President of Sales & Marketing and Executive Director
Mr. Sarvesh Singh
Gender: male
Year Born: 1981
Executive Director
Mr. Mritunjay Kumar Singh
Gender: male
Year Born: 1963
Chief Executive Officer
Dr. Vikas Gupta
Gender: Not Specified
Year Born:
President & Global HR Head
Mr. Rajorshi Ganguli
Gender: male
Year Born: 1971
MD & Executive Director
Mr. Sandeep Derjit Singh
Gender: male
Year Born: 1982
Executive Director
Ms. Madhurima Singh
Gender: female
Year Born: 1965
President & Chief Medical Officer
Dr. Akhilesh D. Sharma
Gender: Not Specified
Year Born: 1969
Executive Chairman
Mr. Basudeo Narian Singh
Gender: male
Year Born: 1941
FAQs about Alkem Laboratories Limited
Who is the CEO of the company?
The CEO is Vikas Gupta.
What is the current market price of the stock?
The current price is ₹5,426.00.
What is the 52-week price range?
The range is ₹4491.65-6439.9.
What is the market capitalization of the company?
The market capitalization is ₹64,875.97 crores.
What is the dividend yield?
The dividend yield is 0.83%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 28.40.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Alkem Laboratories Limited (ISIN: INE540L01014) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹64,875.97 crores and an average daily volume of 193,143 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹45.